VEGFA and retinopathy of prematurity: There are RCTs examining the effectiveness of anti-VEGF and laser, suggesting beneficial outcomes of anti-VEGF, particularly for posterior disease.9 10 A network meta-analysis found lower retreatment rates with laser than with ranibizumab overall, while bevacizumab was associated with the most durable response in Zone I ROP.11